• Explore /
  • Poster
  • / Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

Abstract Poster

Authors

null

Nancy L. Bartlett

Division of Oncology, Washington University School of Medicine, St. Louis, MO

Nancy L. Bartlett , Christopher A. Yasenchak , Khaleel K. Ashraf , William N. Harwin , Robert Brownell Sims , Grzegorz S. Nowakowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04404283

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7571)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7571

Abstract #

TPS7571

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nancy L. Bartlett

First Author: Joshua Brody

First Author: Luis De La Cruz Merino Sr.

First Author: Ian W. Flinn